Analysis of incidence and clinical outcomes in patients with thromboembolic events and invasive exocrine pancreatic cancer

Cancer, 04/23/2012

Thromboembolic events (TEs) are common in exocrine pancreatic cancer, with coagulopathy, erythropoietin–stimulating agent use, and underweight body mass index (BMI) influencing thrombosis timing. TEs, particularly early ones, confer a significantly worse prognosis, suggesting a biological significance, underscoring the relevance of ongoing prophylaxis trials, and raising the question of whether early TEs should be considered a stratification factor for clinical trials.

Print Article Summary Cat 2 CME Report